Hazard ratio in clinical trials.
作者信息
Spruance Spotswood L, Reid Julia E, Grace Michael, Samore Matthew
机构信息
Division of Infectious Diseases, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah 84132-2405, USA.
出版信息
Antimicrob Agents Chemother. 2004 Aug;48(8):2787-92. doi: 10.1128/AAC.48.8.2787-2792.2004.
Abstract
摘要
相似文献
1
Hazard ratio in clinical trials.
Antimicrob Agents Chemother. 2004 Aug;48(8):2787-92. doi: 10.1128/AAC.48.8.2787-2792.2004.
2
[Tromantadine hydrochloride in the treatment of herpes genitalis. A double-blind controlled study].
G Ital Dermatol Venereol. 1985 Jul-Aug;120(4):XLI-XLVI.
3
Challenges to HIV prevention--seeking effective measures in the absence of a vaccine.
N Engl J Med. 2008 Apr 10;358(15):1543-5. doi: 10.1056/NEJMp0802028.
4
[Topical treatment of genital herpes simplex with a pregnene derivative].
Gac Med Mex. 1984 Feb;120(2):59-60.
5
Efficacy of acyclovir in the treatment of recurring herpes labialis, genitalis and acute herpes zoster.
J Chemother. 1989 Jul;1(4 Suppl):1117-8.
6
Short-course oral antiviral treatment for recurrent genital herpes.
Ann Pharmacother. 2003 Dec;37(12):1900-3. doi: 10.1345/aph.1D148.
7
Short-course therapy for recurrent genital herpes and herpes labialis.
J Fam Pract. 2007 Jan;56(1):30-6.
8
Anticipated "slam dunk" treatment fails.
AIDS Read. 2008 Apr;18(4):208.
9
Antiviral drugs today.
N Z Med J. 1984 Dec 12;97(769):852-4.
10
Reformulating the hazard ratio to enhance communication with clinical investigators.
Clin Trials. 2008;5(3):248-52. doi: 10.1177/1740774508091452.
引用本文的文献
1
Divergent Trends by Patient Age in Racial Disparities in Kidney Transplant Access.
Kidney Int Rep. 2025 Jun 4;10(8):2766-2777. doi: 10.1016/j.ekir.2025.05.045. eCollection 2025 Aug.
2
Letter to the Editor Regarding: "Optimizing Bariatric Surgery Outcomes: The Dual Benefits of Preoperative Very‑Low‑Calorie Diets".
Obes Surg. 2025 Aug 11. doi: 10.1007/s11695-025-08160-5.
3
The Hazard Ratio Is Equivalent to an Odds Under the Assumption of Proportional Hazards.
J Patient Cent Res Rev. 2025 Jul 15;12(3):140-143. doi: 10.17294/2330-0698.2156. eCollection 2025 Summer.
4
Statistical Considerations and Challenges with Time-to-Event Analyses for Composite Endpoints in Clinical Trials.
Ther Innov Regul Sci. 2025 Jul 22. doi: 10.1007/s43441-025-00840-9.
5
Deep learning predicts onset acceleration of 38 age-associated diseases from blood and body composition biomarkers in the UK Biobank.
Geroscience. 2025 Jun 27. doi: 10.1007/s11357-025-01702-w.
6
Reshaping the landscape of locoregional treatments for breast cancer liver metastases: A novel, intratumoral, p21-targeted percutaneous therapy increases survival in BALB/c mice inoculated with 4T1 triple negative breast cancer cells in the liver.
PLoS One. 2025 Jun 5;20(6):e0323621. doi: 10.1371/journal.pone.0323621. eCollection 2025.
7
Estimate hazard ratios in small clinical trials without reported hazard ratios.
Discov Oncol. 2025 May 24;16(1):908. doi: 10.1007/s12672-025-02703-z.
8
Survival benefit of secondary prevention medical therapy in takotsubo cardiomyopathy: a Bayesian network meta-analysis.
Eur Heart J Open. 2025 Apr 16;5(3):oeaf040. doi: 10.1093/ehjopen/oeaf040. eCollection 2025 May.
9
Survival analysis for cardiothoracic surgeons: part 6-interpreting time-to-event data.
Indian J Thorac Cardiovasc Surg. 2025 May;41(5):629-644. doi: 10.1007/s12055-025-01911-0. Epub 2025 Mar 8.
10
A Proteomic Signature for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma Predicts Patients at High Risk of Recurrence.
Cancer Res Commun. 2025 Apr 1;5(4):580-593. doi: 10.1158/2767-9764.CRC-23-0460.
本文引用的文献
1
A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group.
Arch Dermatol. 1998 Feb;134(2):185-91. doi: 10.1001/archderm.134.2.185.
2
Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials.
Clin Infect Dis. 1996 Feb;22(2):341-7. doi: 10.1093/clinids/22.2.341.
3
Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.
Ann Intern Med. 1996 Sep 1;125(5):376-83. doi: 10.7326/0003-4819-125-5-199609010-00004.
4
5
Effect of oral acyclovir on pain resolution in herpes zoster: a reanalysis.
J Med Virol. 1993;Suppl 1:93-6. doi: 10.1002/jmv.1890410518.
6
Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group.
Ann Intern Med. 1995 Jul 15;123(2):89-96. doi: 10.7326/0003-4819-123-2-199507150-00002.
7
Evaluating the yield of medical tests.
JAMA. 1982 May 14;247(18):2543-6.
8
Regression modelling strategies for improved prognostic prediction.
Stat Med. 1984 Apr-Jun;3(2):143-52. doi: 10.1002/sim.4780030207.
Zotero 插件